Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound-Guided fluid therapy may cut lung risks in elderly cancer surgery

NCT ID NCT07691944

Disease control Sponsor: First Affiliated Hospital of Chongqing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This trial investigates whether using a special ultrasound score (VExUS) to guide fluid delivery during surgery can lower the chance of lung complications in patients aged 65–80 undergoing minimally invasive esophageal cancer removal. Participants are randomly assigned to receive either VExUS-guided fluid therapy or standard fluid management. The study tracks lung complications, recovery quality, and hospital stay length to see if the ultrasound-guided approach improves outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VExUS score-guided goal-directed fluid therapy (procedure)
What this could lead to
If successful, this approach could reduce serious lung complications after esophageal cancer surgery in elderly patients, potentially improving recovery and shortening hospital stays.
What could go wrong
This is a single-center trial with 126 participants, so results may not apply broadly. The intervention requires specialized ultrasound training, and benefits over standard care may be modest or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 126 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study protocol has been submitted for ethical approval to the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University. A total of 126 patients scheduled for elective thoracoscopic three-incision radical esophagectomy (McKeown MIE) will be recruited from the Department of Anesthesiology, First Affiliated Hospital of Chongqing Medical University between February 2026 and July 2026.

Ages

65 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 65 and 80 years old * Scheduled for elective McKeown MIE * ASA physical status classification I to III * Body mass index (BMI) between 18 kg/m² and 30 kg/m² (exclusive of 18 kg/m²) Exclusion Criteria: * Respiratory failure (SaO₂ \< 60 mmHg and/or PaCO₂ \> 50 mmHg) * Severe cardiac dysfunction (NYHA class III-IV) * Angina pectoris within the past 3 months or acute myocardial infarction (STEMI/NSTEMI) within the past 6 months * Pulmonary hypertension (pulmonary artery systolic pressure, PASP \> 35 mmHg) * Moderate to severe tricuspid stenosis/regurgitation (valve orifice area \< 1.5 cm² / vena contracta width ≥ 0.3 cm) * Decompensated cirrhosis (Child-Pugh class ≥ B) * Chronic kidney disease (CKD stage ≥ 3a) (estimated glomerular filtration rate, eGFR \< 45 mL/min/1.73 m²) * Cognitive impairment (Mini-Mental State Examination, MMSE \< 27) and inability to cooperate with follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal cancer (ESC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal cancer (ESC) Postoperative pulmonary complications (PPCS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.